160 related articles for article (PubMed ID: 36620912)
1. Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022).
Yan J; Zhuang L; Wang Y; Jiang Y; Tu Z; Dong C; Chen Y; Zhu Y
Expert Opin Ther Pat; 2022 Dec; 32(12):1217-1244. PubMed ID: 36620912
[TBL] [Abstract][Full Text] [Related]
2. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
3. Expanding roles of cell cycle checkpoint inhibitors in radiation oncology.
Hauge S; Eek Mariampillai A; Rødland GE; Bay LTE; Landsverk HB; Syljuåsen RG
Int J Radiat Biol; 2023; 99(6):941-950. PubMed ID: 33877959
[TBL] [Abstract][Full Text] [Related]
4. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
Mak JP; Man WY; Chow JP; Ma HT; Poon RY
Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy.
Vakili-Samiani S; Khanghah OJ; Gholipour E; Najafi F; Zeinalzadeh E; Samadi P; Sarvarian P; Pourvahdani S; Kelaye SK; Hamblin MR; Feizi AAH
Mutat Res; 2022; 824():111776. PubMed ID: 35247630
[TBL] [Abstract][Full Text] [Related]
7. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
[TBL] [Abstract][Full Text] [Related]
8. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
Chen J; Jia X; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Biochem Pharmacol; 2021 Jun; 188():114494. PubMed ID: 33684390
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
10. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
11. Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors.
Zhang C; Peng K; Liu Q; Huang Q; Liu T
Crit Rev Oncol Hematol; 2024 Jan; 193():104233. PubMed ID: 38103761
[TBL] [Abstract][Full Text] [Related]
12. WEE1 inhibition and genomic instability in cancer.
Vriend LE; De Witt Hamer PC; Van Noorden CJ; Würdinger T
Biochim Biophys Acta; 2013 Dec; 1836(2):227-35. PubMed ID: 23727417
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
[TBL] [Abstract][Full Text] [Related]
14. WEE1 kinase inhibitor MK-1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status.
Al-Jamaei AH; de Visscher JGAM; Subramanyam VR; Forouzanfar T; Sminia P; Doulabi BZ; Helder MN
Oral Dis; 2023 Oct; 29(7):2640-2649. PubMed ID: 35672254
[TBL] [Abstract][Full Text] [Related]
15. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
[TBL] [Abstract][Full Text] [Related]
16. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
[TBL] [Abstract][Full Text] [Related]
18. Targeting Wee1-like protein kinase to treat cancer.
Stathis A; Oza A
Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms.
Weindl L; Atreya I; Dietrich P; Neubeck S; Neurath MF; Pavel M
Endocr Relat Cancer; 2021 Jul; 28(9):605-620. PubMed ID: 34128828
[TBL] [Abstract][Full Text] [Related]
20. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
